Literature DB >> 15319710

Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.

Julián Benito-León1.   

Abstract

Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quinacrine and chlorpromazine treatment.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15319710     DOI： 10.1097/01.wnf.0000134853.36429.0e

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  16 in total

1.  Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.

Authors:  David A Kocisko; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 2.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

3.  A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.

Authors:  Danielle Beckman; Rafael Linden
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 4.  Prions: Beyond a Single Protein.

Authors:  Alvin S Das; Wen-Quan Zou
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.

Authors:  Jifeng Bian; Hae-Eun Kang; Glenn C Telling
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

6.  Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.

Authors:  Valentina Villa; Michele Tonelli; Stefano Thellung; Alessandro Corsaro; Bruno Tasso; Federica Novelli; Caterina Canu; Albiana Pino; Katia Chiovitti; Domenico Paludi; Claudio Russo; Anna Sparatore; Antonio Aceto; Vito Boido; Fabio Sparatore; Tullio Florio
Journal:  Neurotox Res       Date:  2010-04-20       Impact factor: 3.911

Review 7.  Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy.

Authors:  Karen Vana; Chantal Zuber; Daphne Nikles; Stefan Weiss
Journal:  Cell Mol Neurobiol       Date:  2006-12-07       Impact factor: 5.046

Review 8.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures.

Authors:  Sabrina Cronier; Vincent Beringue; Anne Bellon; Jean-Michel Peyrin; Hubert Laude
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 10.  A review of drug therapy for sporadic fatal insomnia.

Authors:  Pardis Tabaee Damavandi; Martin T Dove; Richard W Pickersgill
Journal:  Prion       Date:  2017-09-03       Impact factor: 3.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.